Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2018-04-09 Board/Management Inform…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics renforce sa gouvernance
Board/Management Information Classification · 99% confidence The document explicitly details changes in the company's leadership structure: the dissociation of the Chairman and CEO roles, the reappointment of Lionel SEGARD as Chairman of the Board, and the nomination of Jean-Philippe MILON as CEO. This content directly relates to changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document is not a formal regulatory filing like a 10-K or an earnings release, but a specific corporate announcement about governance structure.
2018-04-09 French
Rapport financier annuel 2017
Annual Report Classification · 100% confidence The document is titled 'RAPPORT ANNUEL 2017' (Annual Report 2017) for Quantum Genomics. It contains a comprehensive table of contents covering business activities, financial results, risk factors, corporate governance, and the auditor's report. This structure is characteristic of a full annual financial report (10-K equivalent in the French market context). It is not an announcement of a report, but the report itself. FY 2017
2018-03-29 French
Quantum Genomics accroît ses marges de manœuvre opérationnelles en mettant en place une ligne de financement flexible avec Kepler Cheuvreux
Capital/Financing Update Classification · 99% confidence The document announces the establishment of a flexible equity financing line of up to €24 million with Kepler Cheuvreux. This is a direct announcement regarding the company's fundraising and capital structure activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions future events like the communication of a 3-year strategic plan and the publication of 2017 results, the primary, headline-grabbing news is the financing agreement itself. It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Report Publication Announcement (RPA) as it contains substantial detail about the financing terms.
2018-03-05 French
Quantum Genomics Secures Operational Flexibility and Growth Capital through Equity Line Financing with Kepler Cheuvreux
Share Issue/Capital Change Classification · 99% confidence The document announces the implementation of an equity line financing facility of up to €24 million structured with Kepler Cheuvreux. It details the terms, the initial tranche, and the impact on shareholding. This clearly relates to the company raising capital or changing its financing structure. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document is a detailed announcement, not just a brief notice of a report, so RPA/RNS is less appropriate than the specific financial event code.
2018-03-05 English
Quantum Genomics renforce son comité scientifique avec la nomination du Pr Frans Leenen, expert renommé en insuffisance cardiaque
Board/Management Information Classification · 99% confidence The document announces the appointment of Professor Frans Leenen to the company's scientific committee and provides an updated calendar of upcoming events, including an Annual General Meeting (AGM) date (14 juin 2018). The core content is an announcement regarding management/board structure (scientific committee appointment) and future corporate events. This aligns best with the Board/Management Information category (MANG), as the scientific committee members are key personnel advising the board/management on strategy. It is not a formal financial report (10-K, IR, ER) nor a specific proxy/voting document (DEF 14A, PSI).
2018-02-05 French
Quantum Genomics strengthens its Scientific Advisory Board with the appointment of Professor Frans Leenen, a renowned expert in congestive heart failure
Board/Management Information Classification · 98% confidence The document is a press release announcing the appointment of a new expert, Professor Frans Leenen, to the company's Scientific Advisory Board. It contains company news, quotes from management, and a calendar of upcoming events, including the publication dates for financial results. This type of announcement, focusing on management/board changes and general corporate updates, fits best under the 'Board/Management Information' category (MANG). It is not a formal financial report (10-K, IR, ER) nor is it a presentation (IP) or a transcript (CT). Since it is a specific announcement about personnel joining an advisory board, MANG is the most precise fit.
2018-02-05 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.